MyoKardia_Logo_RGB.png
MyoKardia Reports Third Quarter 2018 Financial Results
November 07, 2018 16:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
November 07, 2018 08:01 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
November 05, 2018 08:00 ET | MyoKardia, Inc.
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of Mavacamten’s Effect on...
MyoKardia_Logo_RGB.png
MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
November 05, 2018 08:00 ET | MyoKardia, Inc.
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) MyoKardia...
MyoKardia_Logo_RGB.png
MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
October 30, 2018 07:30 ET | MyoKardia, Inc.
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy Volunteers Presented;...
MyoKardia_Logo_RGB.png
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
October 25, 2018 00:00 ET | MyoKardia, Inc.
First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO,...
MyoKardia_Logo_RGB.png
MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy
October 24, 2018 16:30 ET | MyoKardia, Inc.
Key Remaining Study in Registration Program for oHCM Enables Assessment of Mavacamten’s Potential for Disease Modification SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia,...
MyoKardia_Logo_RGB.png
MyoKardia to Host R&D Day on October 30, 2018
October 22, 2018 08:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
September 24, 2018 08:01 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia to Present at Two Upcoming Investor Conferences in September
August 29, 2018 16:01 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...